Prior to moving to Belgium a year ago to become CEO of eTheRNA immunotherapies NV, Steven Powell was CEO of Cambridge Cognition, where he remains a non-executive director and chair of the board. Cambridge Cognition recently spun off a new entity – Monument Therapeutics – which aims to use cognitive profiles as a biomarker for patients, to be able to predict how they will respond to a treatment.
Cambridge Cognition uses computerized tests to monitor and assess cognitive function – that primarily look at memory and reaction time...